Search hospitals

>

Connecticut

>

New Haven

Yale Cancer Center

Claim this profile

New Haven, Connecticut 06510

Global Leader in Solid Tumors

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Cancer

Conducts research for Pancreatic Cancer

408 reported clinical trials

39 medical researchers

Photo of Yale Cancer Center in New HavenPhoto of Yale Cancer Center in New HavenPhoto of Yale Cancer Center in New Haven

Summary

Yale Cancer Center is a medical facility located in New Haven, Connecticut. This center is recognized for care of Solid Tumors, Breast Cancer, Lung Cancer, Cancer, Pancreatic Cancer and other specialties. Yale Cancer Center is involved with conducting 408 clinical trials across 333 conditions. There are 39 research doctors associated with this hospital, such as Patricia M Lorusso, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.

Area of expertise

1

Solid Tumors

Global Leader

Yale Cancer Center has run 101 trials for Solid Tumors. Some of their research focus areas include:

Stage IV
Stage III
KRAS positive
2

Breast Cancer

Global Leader

Yale Cancer Center has run 83 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative

Top PIs

Clinical Trials running at Yale Cancer Center

Breast Cancer

Solid Tumors

Prostate Cancer

Cancer

Pancreatic Cancer

Lung Cancer

Endometrial Cancer

Ovarian Cancer

Melanoma

Lymphoma

Image of trial facility.

RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant

for Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

sac-TMT + Pembrolizumab

for Breast Cancer

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.

Recruiting

2 awards

Phase 3

3 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Yale Cancer Center?

Where is Yale Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Yale Cancer Center accept?

What awards or recognition has Yale Cancer Center received?